• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Exogenous glutathione exerts a therapeutic effect in ischemic stroke rats by interacting with intrastriatal dopamine
Acta Pharmacol Sin. 2021 May 25. doi: 10.1038/s41401-021-00650-3. Online ahead of print.ABSTRACTWe previously showed that oral administration of exogenous glutathione (GSH) exerted a direct and/or indirect therapeutic effect on ischemic stroke rats, but the underlying mechanisms remain elusive. In the current study, we conducted a quantitative proteomic analysis to explore the pathways mediating the therapeutic effect of GSH in cerebral ischemia/reperfusion (I/R) model rats. Rats were subjected to middle cerebral artery occlusion (MCAO) for 2 h followed by reperfusion. The rats were treated with GSH (250 mg/kg, ig) or levo...
Source: Acta Pharmacologica Sinica - May 26, 2021 Category: Drugs & Pharmacology Authors: He Wang Yi-Sha Du Wen-Shuo Xu Chang-Jian Li Hong Sun Kang-Rui Hu Yuan-Zhuo Hu Teng-Jie Yu Hui-Min Guo Lin Xie Guang-Ji Wang Yan Liang Source Type: research

A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.
CONCLUSIONS: The pharmacologic agent with the most supporting literature is amantadine used for cognitive improvement after TBI. Other neurostimulants with positive, despite more limited, evidence include methylphenidate, modafinil, levodopa, and citalopram. Caution is warranted with other neurostimulants given higher rates of adverse effects or lack of benefit observed in clinical trials. PMID: 33435717 [PubMed - as supplied by publisher]
Source: The Annals of Pharmacotherapy - January 12, 2021 Category: Drugs & Pharmacology Authors: Kakehi S, Tompkins DM Tags: Ann Pharmacother Source Type: research

Pharmacological interventions and rehabilitation approach for enhancing brain self-repair and stroke recovery.
Abstract Neuroplasticity is a natural process occurring in the brain for entire life. Stroke is the leading cause of long term disability and huge medical and financial problem throughout the world. Research conducted over the past decade focused mainly on neuroprotection in the acute phase of stroke while very little studies targets chronic stage. Recovery after stroke depends on the ability of our brain to reestablish structural and functional organization of neurovascular networks. Combining adjuvant therapies and drugs may enhance the repair processes and restore impaired brain functions. Currently, there are ...
Source: Current Neuropharmacology - July 24, 2019 Category: Drugs & Pharmacology Authors: Szelenberger R, Kostka J, Saluk-Bijak J, Miller E Tags: Curr Neuropharmacol Source Type: research

The efficacy and safety of pharmacological treatments for post-stroke aphasia.
Conclusions Current evidence suggests that drugs can improve the prognosis of post-stroke aphasia, such as donepezil, memantine. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvement in the treatment of aphasia after stroke. The trial for galantamine, amphetamine and levodopa in the treatment of aphasia after stroke is limited and inconclusive. PMID: 29984673 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - July 6, 2018 Category: Drugs & Pharmacology Authors: Zhang X, Shu B, Zhang D, Huang L, Fu Q, Du G Tags: CNS Neurol Disord Drug Targets Source Type: research

The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
CONCLUSIONS: Oral administration of Levodopa in the treatment of PD can cause HHcy, which can result in increased occurrence of ischemic stroke. Supplementation of methylcobalamin and folic acid can effectively reduce Hcy level and thereby prevent the occurrence of ischemic stroke. PMID: 27338068 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - June 25, 2016 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

FDA Drug Safety Communication: Ongoing Safety Review of Stalevo and possible increased cardiovascular risk
[08-20-2010] The U.S. Food and Drug Administration (FDA) is evaluating clinical trial data that suggest patients taking Stalevo (a combination of carbidopa/levodopa and entacapone) may be at an increased risk for cardiovascular events (heart attack, stroke, and cardiovascular death) compared to those taking carbidopa/levodopa (sold as the combination product, Sinemet).
Source: FDA Center for Drug Evaluation and Research - What's New - March 2, 2016 Category: Drugs & Pharmacology Source Type: news